##### 



Exhibit 10.51
 ***Text Omitted and Filed SeparatelyConfidential Treatment
RequestedUnder 17 C.F.R. §§ 200.80(b)(4)
and240.24b-2(b)(1)
 LICENSE AGREEMENT
 IDM Pharmexa Party Parties
  Asset Purchase Agreement
  ®
   ARTICLE 1 CERTAIN DEFINITIONS
  Affiliate
 Antigen
 1




---



##### 



AutoVac
 Cancer Field
 Confidential Information
 Effective Date
 EIS® Epitope Identification System
 Epitope
 Existing Library
 Existing Patents
  IDM Reserved Rights
 Infringement Notice
 Indemnitee
 Indemnitor
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)
 2




---



##### 



Invention
 Licensed Know-How
 Licensed Patents
 Patents
 Person
 Pharmexa Field
 Product
 Specific Product ä
 Third Party
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)
 3




---



##### 



ARTICLE 2 LICENSE GRANTS
 Grant of Licenses
 Schedule B-1 IDM Reserved
Rights Schedule B-2 Schedule B-2
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)
 4




---



##### 



Rights Retained by Pharmexa
 Reasonable Access
 Duplicate Copies
 ARTICLE 3 CONSIDERATION FOR LICENSE
 Consideration Section 2.1
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)
 5




---



##### 



ARTICLE 4 PATENTS
 No Assignment Section 2.1
 Patent Filing, Prosecution and Maintenance
    *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)
 6




---



##### 



Infringement Actions
 Infringement Notice
  Section 4.3(b)
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)
 7




---



##### 



Inventions Inventions provided however
 Infringement of Third Party Rights
 ARTICLE 5 CONFIDENTIALITY
 Confidentiality
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)
 8




---



##### 



Exceptions Article 5
 Disclosure Required by Law
 Return of Confidential Information
 9




---



##### 



Injunctive Relief
 Disclosure of Agreement
 Scientific Publications
 ARTICLE 6 REPRESENTATIONS AND WARRANTIES
 General Representations
 Authority
 10




---



##### 



Due
Execution
 No Third Party Approval
 Binding Agreement
 Disclaimers
   ARTICLE 7 INDEMNIFICATION
 Indemnification
 IDM Indemnitee Losses
 11




---



##### 



Pharmexa Indemnitee Section 2.1
 Certain Procedures Regarding Indemnification
 Claim Claim
Notice
   *
    

Confidential
Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)
 12




---



##### 



Limitation on Liability Article
7 Section 5.1
 Resolution of Disputed Indemnification Claim
 Contested Claim
 ARTICLE 8 TERM AND TERMINATION
 Term
 Termination
 Effect of Termination Section 8.2
 Remedy Not Exclusive
 ARTICLE 9 DISPUTE RESOLUTION
 Arbitration
 Dispute
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)
 13




---



##### 



*
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)
 14




---



##### 



ARTICLE 10 MISCELLANEOUS
 Survival
 Force Majeure
 Entire Agreement
 Assignment provided however
 Waivers
 Severance
 Notices
 15




---



##### 



If to IDM:
    
    If to Pharmexa:IDM Pharma, Inc.
9 Parker, Suite 100
Irvine, CA 92618-1605
USA
Attn: Jean-Loup Romet-Lemonne, M.D.
With a copy to:

Cooley Godward LLP
4401 Eastgate Mall
San Diego, CA 92121-1909
USA
Attn: Barbara L. Borden, Esq.
    
    Pharmexa, Inc.
5820 Nancy Ridge Drive
San Diego, CA 92121
USA
Attn: Chief Executive
Officer
With copies to:
Pharmexa A/S
Kogle Allé 6
DK-2970 Hørsholm
Denmark
Attn: Chief Financial Officer
and
Nordlicht & Hand
645 Fifth Avenue
New York, NY 10022
USA
Attn: Brian M. Hand, Esq.
 Costs
 Article and Section Headings and Gender
 16




---



##### 



Counterparts
 Governing Law
 Mutual Drafting
 Schedules
  17




---



##### 



EXECUTION PAGE
EIS LICENSE AGREEMENT
  IDM PHARMA, INC.
    
    
    
    PHARMEXA, INC.By:
    
    /s/ Robert De Vaere
    
    
    
    By:
    
    /s/ Marc HertzName:
    
    Rober De Vaere
    
    
    
    Name:
    
    Marc HertzTitle:
    
    Chief Financial Officer
    
    
    
    Title:
    
    CEO
 18




---



##### 



SCHEDULE A
 LICENSED PATENTS
  *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



[. . . *** . . .]
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



[. . . *** . . .]
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



[. . . *** . . .]
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



[. . . *** . . .]
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



[. . . *** . . .]
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



[. . . *** . . .]
 *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



SCHEDULE B-1
  *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



SCHEDULE B-2
 EXISTING EPITOPE GRANTS
  *
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



*
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



*
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



*
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



*
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



*
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



*
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)




---



##### 



*
    
    Confidential Treatment Requestedunder 17 C.F.R. §§ 200.80(b)(4) and240.24b-2(b)(1)